Andere talen Immunovia AB

Aandelen

IMMNOV

SE0006091997

Beurs gesloten - Nasdaq Stockholm Andere beurzen 12:59:40 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,03 ^SEK	-6,24%		-1,69%	+14,56%

29/04	Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024
29/04	Immunovia benoemt Lisa Ford tot klinisch laboratoriumdirecteur	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director	29/04
Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina	29/04
Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina	29/04
Immunovia Appoints Lisa Ford as Clinical Laboratory Director	29/04
Immunovia publishes the annual report for 2023	29/04
Immunovia Publishes Interim Report for January-March 2024	29/04
Immunovia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04
Invitation to Immunovia's Q1 presentation	23/04
Immunovia announces updated financial calendar	22/04
Immunovia announces positive results from the model-development study for its next-generation pancreatic cancer detection test	22/04
Immunovia AB Announces Positive Results from the Model-Development Study for Its Next-Generation Pancreatic Cancer Detection Test	22/04
Immunovia, Proteomedix Create Assays for Pancreatic Cancer Detection Test	09/04
Immunovia successfully develops assays to measure targeted proteins for its next-generation pancreatic cancer test - moving forward towards model-development study	09/04
Immunovia Successfully Develops Assays to Measure Targeted Proteomedix for Its Next-Generation Pancreatic Cancer Test - Moving Forward Towards Model-Development Study	09/04
Immunovia announces updated financial calendar	12/03
Immunovia Publishes Full Year Report for 2023	21/02
Immunovia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/02
Immunovia AB Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Invitation to Immunovia's Q4 presentation	14/02
Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs	31/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immunovia AB

Aandelen

IMMNOV

SE0006091997

Andere talen

Filters